Viatris Inc. Earnings Recaps
Q1 2026
May 9, 2026
Viatris shares rose 7.6% following Q1 results, driven primarily by solid execution in Greater China and progress on key product approvals that ease growth concerns. The market rewarded the company's pipeline milestones and commercial momentum despite no major changes to guidance.
Key takeaways
- Reported Q1 revenues of $3.5 billion, up 3% year-over-year, with adjusted EBITDA of $1 billion and adjusted EPS of $0.59 per share.
- Strong commercial execution in Greater China significantly contributed to revenue growth; Japan showed improving momentum with the EFFEXOR launch for generalized anxiety disorder.
- Regulatory progress remains on track with one product approved this quarter and five additional decisions expected in the second half, including the contraceptive patch XULANE LO and fast-acting meloxicam.
- Management emphasized disciplined capital allocation, continuing to balance shareholder returns with investments in growth and pipeline development.
- Strategic initiatives to optimize costs and improve operational efficiency are progressing as planned, supporting margin sustainability.
Q3 2025
Nov 6, 2025
Viatris reported a robust Q3 2025, with solid revenue growth and an increase in full-year guidance, bolstered by strong commercial execution and advancements in its product pipeline.
Key takeaways
- Achieved 1% operational revenue growth (excluding Indore), consistent with expectations, driven by strong performance in Europe and emerging markets.
- Raised full-year guidance for total revenues, adjusted EBITDA, and adjusted EPS due to positive momentum within the business.
- Significant progress in pipeline development, including a forthcoming NDA for fast-acting meloxicam and advancements in Phase III programs for cenerimod and selatogrel.
- Returned over $920 million to shareholders year-to-date, including $500 million in share repurchases, on track to exceed $1 billion in capital returns for the year.
- Strategic review targeting operational efficiencies and growth reinvestment is underway, with opportunities for meaningful cost savings identified.